SEPTInvestingStart Free

CGEM 10-Q: SEC filing

Cullinan Therapeutics

Filed with the SEC on · accession 0001193125-26-454417

CGEM filed a 10-Q (quarterly report) with the SEC on Nov 10, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.

Summary of the filing

Cullinan Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing financial results and updates on its clinical-stage pipeline programs including velinotamig, CLN-978, CLN-617, CLN-049, and zipalertinib, along with licensing and collaboration arrangements.

For details, click here →How to read a 10-Q →

Key details

FilerCullinan Therapeutics, Inc.
License agreement counterpartyGenrix Biopharmaceutical Co., Ltd.
Collaboration partnerPearl Taiho Pharma
At-the-market equity offering sales agentTD Cowen

✦ Ask GOAX AI about this filing — what it means for CGEM, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for CGEM?

Click here

Frequently asked questions

What did CGEM file with the SEC on Nov 10, 2026?

CGEM filed a 10-Q (SEC filing). Cullinan Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing financial results and updates on its clinical-stage pipeline programs including velinotamig, CLN-978, CLN-617, CLN-049, and zipalertinib, along with licensing and collaboration arrangements.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

Other CGEM SEC filings

Get alerts when CGEM files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
CGEM overviewCGEM analysisCGEM newsLatest SEC filings